Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Rhabdomyosarcoma
What role do genetic and molecular profiling play in predicting which patients with high-risk localized RMS benefit from maintenance chemotherapy with vinorelbine and low-dose cyclophosphamide?
Related Questions
How would you manage aplastic anemia refractory to multiple agents?
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
What is your diagnostic and treatment approach to pediatric patients with erythrocytosis?
What adverse events would make you switch off nivo + AVD therapy and to what second line therapy in patients with Hodgkin Lymphoma?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
Do you use direct oral anticoagulants to treat port-a-cath related VTE in patients with an active malignancy?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
With the data from AALL1731, how is blinatumomab being implemented for SR and HR leukemia patients not previously planned/randomized to receive blinatumomab?
